Home Medical stocks Raffles Medical Group Ltd’s (SGX:BSL) Dismal Stock Performance Reflects Weak Fundamentals –...

Raffles Medical Group Ltd’s (SGX:BSL) Dismal Stock Performance Reflects Weak Fundamentals – Simply Wall St News

115
0

It is hard to get excited after looking at Raffles Medical Group’s (SGX:BSL) recent performance, when its stock has declined 14% over the past three months. To decide if this trend could continue, we decided to look at its weak fundamentals as they shape the long-term market trends. In this article, we decided to focus on Raffles Medical Group’s ROE.

Return on equity or ROE is a key measure used to assess how efficiently a company’s management is utilizing the company’s capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

View our latest analysis for Raffles Medical Group

How To Calculate Return On Equity?

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

So, based on the above formula, the ROE for Raffles Medical Group is:

5.6% = S$49m ÷ S$879m (Based on the trailing twelve months to June 2020).

The ‘return’ refers to a company’s earnings over the last year. Another way to think of that is that for every SGD1 worth of equity, the company was able to earn SGD0.06 in profit.

Why Is ROE Important For Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or “retain”, we are then able to evaluate a company’s future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

Raffles Medical Group’s Earnings Growth And 5.6% ROE

At first glance, Raffles Medical Group’s ROE doesn’t look very promising. A quick further study shows that the company’s ROE doesn’t compare favorably to the industry average of 7.0% either. For this reason, Raffles Medical Group’s five year net income decline of 3.5% is not surprising given its lower ROE. We reckon that there could also be other factors at play here. For instance, the company has a very high payout ratio, or is faced with competitive pressures.

So, as a next step, we compared Raffles Medical Group’s performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 4.5% in the same period.

past-earnings-growth
SGX:BSL Past Earnings Growth October 12th 2020

Earnings growth is an important metric to consider when valuing a stock. It’s important for an investor to know whether the market has priced in the company’s expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. Is BSL fairly valued? This infographic on the company’s intrinsic value has everything you need to know.

Is Raffles Medical Group Efficiently Re-investing Its Profits?

Raffles Medical Group’s declining earnings is not surprising given how the company is spending most of its profits in paying dividends, judging by its three-year median payout ratio of 63% (or a retention ratio of 37%). With only a little being reinvested into the business, earnings growth would obviously be low or non-existent.

Additionally, Raffles Medical Group has paid dividends over a period of at least ten years, which means that the company’s management is determined to pay dividends even if it means little to no earnings growth. Based on the latest analysts’ estimates, we found that the company’s future payout ratio over the next three years is expected to hold steady at 74%. Regardless, the future ROE for Raffles Medical Group is predicted to rise to 7.1% despite there being not much change expected in its payout ratio.

Conclusion

Overall, we would be extremely cautious before making any decision on Raffles Medical Group. The company has seen a lack of earnings growth as a result of retaining very little profits and whatever little it does retain, is being reinvested at a very low rate of return. That being so, the latest industry analyst forecasts show that the analysts are expecting to see a huge improvement in the company’s earnings growth rate. To know more about the company’s future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

Promoted
When trading Raffles Medical Group or any other investment, use the platform considered by many to be the Professional’s Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].

https://simplywall.st/stocks/sg/healthcare/sgx-bsl/raffles-medical-group-shares/news/raffles-medical-group-ltds-sgxbsl-dismal-stock-performance-reflects-weak-fundamentals/
https://simplywall.st/stocks/sg/healthcare/sgx-bsl/raffles-medical-group-shares/news/raffles-medical-group-ltds-sgxbsl-dismal-stock-performance-reflects-weak-fundamentals/

This site uses Akismet to reduce spam. Learn how your comment data is processed.